Find your path to Alex
414 people in our graph share verified history with Alex — schools, employers, funds. One of them is your warm intro.
Charles GrummittunlockedAlex: together at Adaptimmune (2015–2016)
Alex: together at Adaptimmune
×4Alex: together at University of Cambridge
Alex: together at Peptone
About
Alex Pasteur joined F-Prime in 2012 as a London-based Partner focused on therapeutics and life sciences investments. He was a founding investor in ARTBIO, Tenpoint Therapeutics and Orchard Therapeutics, and has worked in healthcare investing since 2001, previously at MVM Life Science Partners. He holds an M.A. in Natural Sciences and a PhD in Chemistry, both from Cambridge University.
Contact· self-published, not guessed
Invests in
BiotechDigital Health
Experience
- F-Prime Capital PartnersPartnercurrent2012 — presentLondon Area, United Kingdom
- Tenpoint Therapeutics, Ltd.Non Executive Directorcurrent2020 — presentGreater London, England, United Kingdom
- NodTheraNon Executive Directorcurrent2018 — presentBoston, Massachusetts, United States
- GenomicsNon Executive Directorcurrent2018 — presentOxford, England, United Kingdom
- PeptoneNon Executive Directorcurrent2022 — presentLondon Area, United Kingdom
- PulmocideNon Executive Directorcurrent2013 — presentLondon Area, United Kingdom
- Shift BioscienceNon Executive Directorcurrent2022 — present
- CastorBoard Observercurrent2021 — presentAmsterdam, North Holland, Netherlands
- ARTBIONon Executive Directorcurrent2021 — presentBoston, Massachusetts, United States
- OwkinNon Executive Directorcurrent2019 — presentParis, Île-de-France, France
- OvivaNon Executive Director2016 — 2026Zurich, Switzerland
- Arvelle Therapeutics (Acquired by Angelini Pharma in 2021)Non Executive Director (took over from late Tom Beck)2020 — 2021Zug, Switzerland
- Orchard Therapeutics (NASDAQ: ORTX) acquired by Kyowa Kirin in 2023Founding CEO, then Non Executive Director2015 — 2018London Area, United Kingdom
- Acacia Pharma (EURONEXT BRUSSELS: ACPH) acquired by Eagle Pharmaceuticals in 2022Non Executive Director2013 — 2018Greater Cambridge Area
- AdaptimmuneBoard Observer, Adaptimmune Therapeutics PLC (NASDAQ: ADAP)2015 — 2016Greater Oxford Area
- MVMPartner2005 — 2012London and Boston
- Gateway FundInvestment Manager2001 — 2005Greater Cambridge Area
- OC&CConsultant1996 — 1999London Area, United Kingdom
Skills & more
Biopharmaceuticals6Biotechnology49Business Development7Business Planning6Business Strategy17Clinical Development2Commercialization4Corporate Development8Corporate Finance3Drug Development1Drug Discovery2Due Diligence13
+8 more
Emerging MarketsEntrepreneurshipFinancial ModelingHealthcareInvestment BankingInvestmentsInvestor RelationsLife SciencesFrom Alex's professional profile.
Investments
Board seats
Acacia PharmaAdaptimmune TherapeuticsArvelle TherapeuticsCastorGenomics LtdNodthera, Inc.Oviva AGOwkin, Inc.Peptone LtdPulmocide LtdShift Bioscience Ltd
Investor
ARTBIO, Inc.Orchard Therapeutics PLCTenpoint Therapeutics Holdings Ltd
Per the firm's website.
Colleagues at F-Prime Capital
Abby Wagner
Senior Accountant at F-Prime Capital Partners
Abdul Abdirahman
Principal at F-Prime Capital Partners
Allan Galper
Vice President & Associate General Counsel at F-Prime Capital Partners
Allison MacLeod
Venture Partner at F-Prime Capital Partners
Amber Cai
Venture Partner at F-Prime Capital Partners
Amrit Jalan
Investor at Fine Structures Ventures
Andrew Bognanni
Director of Finance at F-Prime Capital Partners
Bala Varadhan
Principal at F-Prime Capital Partners
Network14
Carl ByersScout
Partner at F-Prime Capital Partners
David JegenScout
Managing Partner, Tech Fund at F-Prime Capital Partners
Davor HebelScout
Managing Partner at Eight Roads Ventures
Sandor PalfyScout
Venture Partner at F-Prime Capital Partners
Abdul Abdirahman
Principal at F-Prime Capital Partners
Bala Varadhan
Principal at F-Prime Capital Partners
Betsy Mulé
Principal at F-Prime Capital Partners
Brett Cook
Partner at F-Prime Capital Partners
Brian Yordy
Principal at F-Prime Capital Partners
Chong Xu
Partner at F-Prime Capital Partners
Connie Li
Principal at F-Prime Capital Partners
Erica Lee
Principal at F-Prime Capital Partners
▶2 more connections
Investors connected to Alex in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Alex Pasteur?
- Alex Pasteur joined F-Prime in 2012 as a London-based Partner focused on therapeutics and life sciences investments. He was a founding investor in ARTBIO, Tenpoint Therapeutics and Orchard Therapeutics, and has worked in healthcare investing since 2001, previously at MVM Life Science Partners. He holds an M.A. in Natural Sciences and a PhD in Chemistry, both from Cambridge University.
- Where does Alex Pasteur work?
- Alex Pasteur is Partner, PhD at F-Prime Capital.
- What does Alex Pasteur invest in?
- Alex Pasteur invests in Biotech, Digital Health.
- What check size does Alex Pasteur write?
- Alex Pasteur typically writes checks of $100K – $10M.
- What boards does Alex Pasteur sit on?
- Alex Pasteur holds tracked board seats at Acacia Pharma, Adaptimmune Therapeutics, Arvelle Therapeutics, Castor, Genomics Ltd, Nodthera, Inc., Oviva AG, Owkin, Inc., Peptone Ltd, Pulmocide Ltd.
- What companies has Alex Pasteur invested in?
- Investments tracked here include ARTBIO, Inc., Orchard Therapeutics PLC, Tenpoint Therapeutics Holdings Ltd.
- Where did Alex Pasteur go to school?
- Alex Pasteur studied at University of Cambridge (PhD, Chemistry); University of Cambridge (Master of Arts (MA), Natural Sciences).
Same school
Also attended University of Cambridge1,602
Stewart ButterfieldCo-founder of Slack and FlickrDemis HassabisCo-founder & CEO of Google DeepMindNiko BonatsosFounder and Managing Partner of VerdictGeorgia StevensonInvestor at Index VenturesHannah SealInvestor at Index VenturesLeah von SiemensPartner at Manta Ray Ventures
+ 1,596 more
Shared employers
Also worked at Tenpoint Therapeutics, Ltd.4
Also worked at NodThera8
Mira ChaurushiyaManaging Director at Westlake Village BioPartnersKatie Bodner SpielbergPrincipal at 5AM VenturesZhizhong YaoPartner at Sofinnova PartnersNIGEL CROCKETTExecutive Officer at BicycleGeoff McDonoughExecutive Team / Board at NodtheraChris GuiffreExecutive Team at Nodthera
+ 2 more
